M&A Deal Summary

Indivior Acquires Opiant Pharmaceuticals

On November 14, 2022, Indivior acquired life science company Opiant Pharmaceuticals for 145M USD

Acquisition Highlights
  • This is Indivior’s 1st transaction in the Life Science sector.
  • This is Indivior’s largest (disclosed) transaction.
  • This is Indivior’s 1st transaction in the United States.
  • This is Indivior’s 1st transaction in California.

M&A Deal Summary
Date 2022-11-14
Target Opiant Pharmaceuticals
Sector Life Science
Buyer(s) Indivior
Deal Type Add-on Acquisition
Deal Value 145M USD
Advisor(s) Lazard Ltd. (Financial)
Latham & Watkins (Legal)

Target

Opiant Pharmaceuticals

Santa Monica, California, United States
Opiant Pharmaceuticals is a biopharmaceutical company developing treatments for addiction and drug overdose leveraging intranasal and injectable delivery technologies. Opiant Pharmaceuticals was founded in 2005 and is based in Santa Monica, California.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Indivior

North Chesterfield, Virginia, United States
Category Company
Sector Life Science
Employees1,000
Revenue 1.1B USD (2023)
DESCRIPTION

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy, health policy and evidence-based best practice models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavor, and the tagline “Focus on you” makes the company’s commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its robust, global opioid dependence portfolio featuring SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII), SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX® (buprenorphine) Sublingual Tablet, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic diseases of addiction – including opiate overdose, alcohol use disorders and cocaine intoxication. It also is pursuing novel product candidates in related mental health disorders such as schizophrenia. Indivior is based in North Chesterfield, Virginia.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2022) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal